Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in Distal Ulcerative Colitis
NCT00309660Phase 2Unknown
- Sponsor
- Herlev Hospital
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of rosiglitazone in ulcerative colitis (UC), sponsored by Herlev Hospital. Primary endpoint: Clinical response at 14 days. Status: unknown.
02
Drugs
rosiglitazone
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00309660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309660.